Liquidia (LQDA) Non Operating Income (2020 - 2026)
Liquidia's (LQDA) quarterly Non Operating Income came in at -$4.7 million in Q1 2026, down 60.5% year-on-year from -$12.0 million in Q1 2025, and up 9.75% quarter-over-quarter from -$5.2 million in Q4 2025.
Liquidia (LQDA) Non Operating Income (2020 - 2026) Analysis & Trends
Liquidia's Non Operating Income history runs 7 years deep, the most recent figure standing at -$4.7 million for Q1 2026.
- On a quarterly basis, Non Operating Income fell 60.5% year-over-year to -$4.7 million in Q1 2026; TTM through Mar 2026 was -$19.3 million, a 123.26% decrease from a year earlier, with the FY2025 full-year figure at -$17.5 million, down 150.79% from the prior year.
- Non Operating Income rose to -$4.7 million in Q1 2026 per LQDA's latest filing, from -$5.2 million in the prior quarter.
- Across five years, Non Operating Income topped out at -$36000.0 in Q4 2022 and bottomed at -$5.3 million in Q3 2025.
- The 5-year median for Non Operating Income is -$1.5 million (2022), against an average of -$2.2 million.
- Across the five-year window, Non Operating Income surged 82.09% in 2022 and plunged 2716.67% in 2023, its largest moves.
- Year by year, Non Operating Income stood at -$36000.0 in 2022, then plunged by 2716.67% to -$1.0 million in 2023, then slumped by 136.98% to -$2.4 million in 2024, then sank by 117.73% to -$5.2 million in 2025, then increased by 9.75% to -$4.7 million in 2026.
- Per Business Quant, the three latest LQDA Non Operating Income figures stand at -$4.7 million (Q1 2026), -$5.2 million (Q4 2025), and -$5.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn | -4.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.72 Mn |
| Dec 31, 2025 | -5.23 Mn |
| Sep 30, 2025 | -5.30 Mn |
| Jun 30, 2025 | -4.07 Mn |
| Mar 31, 2025 | -2.94 Mn |
| Dec 31, 2024 | -2.40 Mn |
| Sep 30, 2024 | -1.84 Mn |
| Jun 30, 2024 | -1.47 Mn |
| Mar 31, 2024 | -1.28 Mn |
| Dec 31, 2023 | -1.01 Mn |
| Sep 30, 2023 | -899,000.00 |
| Jun 30, 2023 | -692,000.00 |
| Mar 31, 2023 | -2.51 Mn |
| Dec 31, 2022 | -36,000.00 |
| Sep 30, 2022 | -261,000.00 |
| Jun 30, 2022 | -477,000.00 |
| Mar 31, 2022 | -1.47 Mn |
| Dec 31, 2021 | -201,000.00 |
| Sep 30, 2021 | -201,000.00 |
| Jun 30, 2021 | -198,000.00 |